Skip to main content

FibroBiologics, Inc.

corporate_fare Company Profile

FibroBiologics, Inc.

FBLG·NASDAQ·Life Sciences·CIK 0001958777

FibroBiologics, Inc. is a clinical-stage biotechnology company that develops and commercializes fibroblast-based therapies for chronic diseases with significant unmet medical needs. These diseases include wound healing, multiple sclerosis (MS), degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications such as thymic involution reversal using a thymic organoid. The company's most advanced product candidates are CYWC628, CYPS317, CYMS101, and CybroCell™. FibroBiologics was initially formed in April 2021 as FibroBiologics, LLC, a Texas limited liability company, and converted to a Delaware corporation in December 2021 under the name Fibrobiologics, Inc. On April 12, 2023, the company changed its name to FibroBiologics, Inc. The company was formed based on intellectual property obtained from its former parent, SpinalCyte LLC (d/b/a FibroGenesis), through a patent assignment agreement and an intellectual property cross-licensing agreement. Preclinical research and development related to this intellectual property occurred under FibroGenesis prior to FibroBiologics' inception. The company's technology platform utilizes fibroblasts, which are a main cell type of connective tissue, capable of regenerating tissue and organs. While historically believed to primarily produce the extracellular matrix, fibroblasts have also demonstrated roles in immune modulation and maintaining stem cell niches, and are important in every stage of wound healing.

FibroBiologics, Inc. (NASDAQ:FBLG) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 47 items for FBLG at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • FibroBiologics' Fibroblast Technology Shows Promise in Burn Treatment, Targets $2.55B Market
  • CFO Buys $28,973 in Open Market Shares Amidst Company Challenges
  • FibroBiologics Secures U.S. Patent for Osteoporosis Cell Therapy
  • FibroBiologics Reports Going Concern Doubt, Nasdaq Delisting Risk, and Material Weakness in Annual Filing
  • Shareholders Approve Reverse Stock Split and Significant Warrant Share Issuances to Address Nasdaq Compliance

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$18.65M
Diluted EPS
-$0.42
Op. Cash Flow
-$16.39M
Free Cash Flow
-$16.66M
Operating Income
-$16.65M
Cash & Equivalents
$4.89M
Debt / Equity
0.00×
Shares Outstanding
44.66M sh
Source: 10-K · filed 2026-03-13 · accession 0001193125-26-106216
$0.722 +2.41% today
52-week range · as of 2026-10-08 $0.62 – $10.33
Market cap
$6.34M
Volume
50.3K (0.6× avg)
3-mo avg 86.4K
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed FBLG - Filings & News (Page 3)

FBLG
Mar 12, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.350
Real-time Price: $0.722 info
Change: Reverse Stock Split info
Market Cap: $6.338M info
FBLG
Mar 03, 2026, 8:00 AM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $0.4282
Real-time Price: $0.722 info
Change: Reverse Stock Split info
Market Cap: $6.338M info
FBLG
Mar 02, 2026, 8:41 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.3485
Real-time Price: $0.722 info
Change: Reverse Stock Split info
Market Cap: $6.338M info
FBLG
Feb 24, 2026, 4:06 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $0.2675
Real-time Price: $0.722 info
Change: Reverse Stock Split info
Market Cap: $6.338M info
FBLG
Feb 23, 2026, 4:18 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.253
Real-time Price: $0.722 info
Change: Reverse Stock Split info
Market Cap: $6.338M info
FBLG
Feb 06, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.2517
Real-time Price: $0.722 info
Change: Reverse Stock Split info
Market Cap: $6.338M info
FBLG
Jan 02, 2026, 5:16 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.231
Real-time Price: $0.722 info
Change: Reverse Stock Split info
Market Cap: $6.338M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets